Compare Adaptive Biotechnologies Corp (ADPT) vs QUALCOMM, Inc. (QCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Adaptive Biotechnologies Corp vs QUALCOMM, Inc. — how do they compare? Adaptive Biotechnologies Corp trades at $25.15 (market cap $4.04B), while QUALCOMM, Inc. trades at $163.72 (market cap $170.81B). The key difference: QUALCOMM, Inc. is far larger — about 42.3× Adaptive Biotechnologies Corp's market cap, and QUALCOMM, Inc. pays a 2.26% dividend while Adaptive Biotechnologies Corp pays none. Which is the better fit depends on your goals.
| ADPT | QCOM | |
|---|---|---|
Market Cap | $4.04B | $170.81B |
Sector | Health | Technology |
52-Week High | $25.45 | $251.10 |
52-Week Low | $12.30 | $124.07 |
Enterprise Value | $4.10B | $177.78B |
Dividend Yield | — | 2.26% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADPT trades at $25.45, up 2.09% today, near its 52-week high. The stock shows bullish technical signals with support at $25 and resistance at $26. Revenue growth accelerated to $277M in 2025, though net losses persist. Recent news highlights a strategic separation of its MRD and Immune Medicine businesses, aiming to unlock value.
Outlook is cautiously optimistic with 65% analyst buy ratings and a $25.50 price target. Key opportunities include MRD segment profitability and separation benefits, while risks involve sustained losses, competitive pressures, and execution challenges in the business split.
Qualcomm (QCOM) trades at $162.17, down 3.39% on the day, with mixed technical signals showing bearish moving averages but neutral oscillators. The company reported strong revenue of $44.28B in 2025 but saw net income decline to $5.54B, reflecting margin pressures. Recent news highlights Qualcomm's AI and data center expansion efforts, including the 'Dragonfly' AI platform announcement at COMPUTEX 2026, while facing increased competition from Nvidia in the PC chip market.
The outlook remains balanced with a consensus price target of $200.56 suggesting 24% upside, but near-term headwinds include smartphone market softness and margin compression. Long-term growth drivers in automotive and AI inference markets provide opportunity, though execution risks and competitive threats from chip rivals pose challenges for shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Adaptive Biotechnologies Corp
Adaptive Biotechnologies Corp is a commercial-stage company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease in patients with select blood cancers.
Read more on ADPT →About QUALCOMM, Inc.
Qualcomm develops and licenses wireless technology and designs chips for smartphones. The company's key patents revolve around CDMA and OFDMA technologies, which are standards in wireless communications that are the backbone of all 3G and 4G networks. The firm is a leader in 5G network technology as well. Qualcomm's IP is licensed by virtually all wireless device makers. The firm is also the world's largest wireless chip vendor, supplying nearly every premier handset maker with leading-edge processors. Qualcomm also sells RF-front end modules into smartphones and chips into automotive and Internet of Things markets.
Read more on QCOM →
